Gemcitabine

For research use only.

Catalog No.S1714 Synonyms: LY-188011, NSC 613327

85 publications

Gemcitabine  Chemical Structure

Molecular Weight(MW): 263.2

Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Gemcitabine has been cited by 85 publications

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Gemcitabine, a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy.
In vitro

Gemcitabine results in 50% inhibition of growth in the CCRF-CEM human leukemia cell culture assay with IC50 of 1 ng/ml. Gemcitabine combined with deoxycytidine provides about a 1000-fold decrease in biological activity. [1] Gemcitabine combined with C225 results in additive cytotoxic effects that increased with increasing gemcitabine concentrations in human pancreatic carcinoma L3.6pl cells. [2] Gemcitabine combined with Cisplatin results in synergistic effect in wild-type A2780 and cisplatin-resistant ADDP cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MV-4-11 NYPvNG5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHDbIJKSzVyPUCuNFAxPDV6IH7N MWrTRW5ITVJ?
ES4 M1fiZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnHTWM2OD1yLkCwNFY2OyCwTR?= NFWzUGRUSU6JRWK=
ACHN NV;1NI54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwMECwPFg4KG6P NYrCVoZGW0GQR1XS
KYSE-510 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HEcGlEPTB;MD6wNFA6PzVibl2= Ml3nV2FPT0WU
EW-7 MoDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jK[GlEPTB;MD6wNFI2QCCwTR?= MUDTRW5ITVJ?
BFTC-905 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHTTlVKSzVyPUCuNFA2OTVibl2= MYLTRW5ITVJ?
KE-37 Mlr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzyOZhsUUN3ME2wMlAxPTZzIH7N MWTTRW5ITVJ?
SBC-5 MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz1TWM2OD1yLkCwOVchdk1? Mk[5V2FPT0WU
NKM-1 MoXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jOSmlEPTB;MD6wNFcxQSCwTR?= NYTGVJlZW0GQR1XS
RH-1 M3;O[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\3XFdIUUN3ME2wMlAxPzF6IH7N MlvaV2FPT0WU
ALL-PO MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2S4[mlEPTB;MD6wNFg{KG6P NXXIN2dOW0GQR1XS
QIMR-WIL MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3Re5hKSzVyPUCuNFA5QTRibl2= NVzwS2s4W0GQR1XS
A375 NEDIOJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13LTGlEPTB;MD6wNFk6PSCwTR?= MUTTRW5ITVJ?
SIG-M5 NHrPXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXrXYpKSzVyPUCuNFExPCCwTR?= MYXTRW5ITVJ?
KGN MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ftTmlEPTB;MD6wNVA5KG6P MWXTRW5ITVJ?
EW-13 NFPJW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILmWGJKSzVyPUCuNFEyOiCwTR?= M1[3bXNCVkeHUh?=
NCI-SNU-1 M2\1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4POW2lEPTB;MD6wNVYhdk1? MYnTRW5ITVJ?
PSN1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTsWZI{UUN3ME2wMlAyPjVibl2= NFvNUHhUSU6JRWK=
HUTU-80 M4DZXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMEG2OkBvVQ>? M1HW[XNCVkeHUh?=
EW-16 NH2xSHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXHemxYUUN3ME2wMlAzOyCwTR?= NVzteJVvW0GQR1XS
786-0 NIHpdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMEKzJI5O MkexV2FPT0WU
ES1 M{\BRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHu1eIRKSzVyPUCuNFI3QCCwTR?= NIe5fW1USU6JRWK=
RKO NYnCOJhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnyOXZ[UUN3ME2wMlAzPzlibl2= NYTkdpRWW0GQR1XS
ESS-1 MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUeoZKUUN3ME2wMlAzQDZibl2= MWDTRW5ITVJ?
SK-UT-1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTBwMEK5O{BvVQ>? M3HuTnNCVkeHUh?=
LB2241-RCC NHPL[IFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTBwMEOxPEBvVQ>? NE\QWm1USU6JRWK=
CHL-1 NIq1ZmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi0SmEzUUN3ME2wMlA{OjRibl2= M4r1b3NCVkeHUh?=
SW1783 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHGSIVsUUN3ME2wMlA{OzZibl2= MXHTRW5ITVJ?
MEL-JUSO NG\0VpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3u2U2lEPTB;MD6wN|kyKG6P NWfzV41PW0GQR1XS
HT-29 NFm3fpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljBTWM2OD1yLkC0NVMhdk1? NV\ZSINzW0GQR1XS
SNG-M NWfQU4FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfXSYRKSzVyPUCuNFQzPSCwTR?= Ml\LV2FPT0WU
TE-15 M2rs[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;PWFB4UUN3ME2wMlA1PjRibl2= NXq5OZpFW0GQR1XS
HOS M1n4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\5TWM2OD1yLkC0PEBvVQ>? Ml;GV2FPT0WU
BB65-RCC NWXaVFVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3NUnhJUUN3ME2wMlA2OTJibl2= MWTTRW5ITVJ?
HCE-4 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TZe2lEPTB;MD6wOVI5KG6P Mo[yV2FPT0WU
MHH-ES-1 NFPPRnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEWzNUBvVQ>? MVXTRW5ITVJ?
RPMI-7951 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMEW0NUBvVQ>? NWDBZnBiW0GQR1XS
IST-SL2 NVLRbWJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGn0NGFKSzVyPUCuNFU5PCCwTR?= NWr0TXlnW0GQR1XS
CMK NVToWmpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMEW4OkBvVQ>? M17PUnNCVkeHUh?=
GR-ST NX7DellRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f6emlEPTB;MD6wOVk2KG6P MV\TRW5ITVJ?
NALM-6 MmnkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljXTWM2OD1yLkC2NlIhdk1? Mo\iV2FPT0WU
RPMI-6666 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr5UWFKSzVyPUCuNFY2OiCwTR?= NHLtWGRUSU6JRWK=
LC-2-ad Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwME[1N{BvVQ>? MmDMV2FPT0WU
ARH-77 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf0eYdsUUN3ME2wMlA4OTFibl2= NXjCUnkyW0GQR1XS
IST-MEL1 MmrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGX3ZpJKSzVyPUCuNFczPiCwTR?= MmrBV2FPT0WU
SW1710 M4\nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPBTWM2OD1yLkC3OVEhdk1? M4T6fXNCVkeHUh?=
DEL NETzSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrrdI5FUUN3ME2wMlA5QDdibl2= M4rIVHNCVkeHUh?=
AGS MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInk[WpKSzVyPUCuNFkxOiCwTR?= NI\HTlhUSU6JRWK=
NCI-H2122 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi2TWM2OD1yLkC5OFYhdk1? MoHpV2FPT0WU
HSC-4 M1LjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTyTWM2OD1yLkGwNkBvVQ>? M{LLSHNCVkeHUh?=
AM-38 NXHBdJhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMUKxJI5O NHKyb49USU6JRWK=
769-P MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LRSGlEPTB;MD6xNlMhdk1? MUDTRW5ITVJ?
RT-112 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUK3JI5O MVXTRW5ITVJ?
MCF7 NFHmTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTrZVZ[UUN3ME2wMlE{PiCwTR?= NFL3dWlUSU6JRWK=
IGROV-1 NX3Re4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELufIpKSzVyPUCuNVQ2KG6P NYTTRm1iW0GQR1XS
OCI-AML2 MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorJTWM2OD1yLkG0O{BvVQ>? NUfkZ3dCW0GQR1XS
NCI-H1299 MlvYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMUW3JI5O M1L0bnNCVkeHUh?=
A431 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjNTWM2OD1yLkG4N{BvVQ>? MYnTRW5ITVJ?
SW982 M{XoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7UTWM2OD1yLkKxN{BvVQ>? NE\jUVNUSU6JRWK=
BB30-HNC MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzlWnhGUUN3ME2wMlI{OSCwTR?= NXXVcYY5W0GQR1XS
ACN MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TDZ2lEPTB;MD6yOFQhdk1? NITsTZdUSU6JRWK=
647-V M{DENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\LW5VKSzVyPUCuNlQ5KG6P MkjyV2FPT0WU
SK-PN-DW MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMk[2JI5O NFnhVFZUSU6JRWK=
LCLC-97TM1 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX64PYtHUUN3ME2wMlI3PyCwTR?= MUXTRW5ITVJ?
LB1047-RCC NYHCSXFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LqWGlEPTB;MD6yOlkhdk1? NIjiVHJUSU6JRWK=
A2780 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mybmlEPTB;MD6yO{BvVQ>? NX[1dI0zW0GQR1XS
C-33-A MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy1SlZKSzVyPUCuNlc{KG6P MU\TRW5ITVJ?
NCI-H2228 M{LxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwM{G0JI5O NH7NT2dUSU6JRWK=
TE-5 M{fqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;RTWM2OD1yLkOxOkBvVQ>? NHfERndUSU6JRWK=
HC-1 M{L1N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L5b2lEPTB;MD6zNlchdk1? NUP0THY1W0GQR1XS
SK-MES-1 M3rld2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonHTWM2OD1yLkOyPEBvVQ>? MXrTRW5ITVJ?
NCI-H1355 Mkn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLidlczUUN3ME2wMlM5OSCwTR?= Mk\LV2FPT0WU
YKG-1 NFH6T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu0WHQ{UUN3ME2wMlQyQSCwTR?= MlPxV2FPT0WU
RS4-11 NHXvOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT3TWM2OD1yLkSzN{BvVQ>? M4[4TnNCVkeHUh?=
Daoy MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2K2OmlEPTB;MD60OVYhdk1? MmLrV2FPT0WU
A3-KAW NHvtU5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjwfY96UUN3ME2wMlU2OSCwTR?= NWTjTINYW0GQR1XS
SK-MEL-30 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYT5eWZxUUN3ME2wMlU2PCCwTR?= MWfTRW5ITVJ?
U031 NXm2O2h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzzTWhKSzVyPUCuOVY2KG6P MlnjV2FPT0WU
SK-LMS-1 NHH4epVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn0RW9FUUN3ME2wMlU4QCCwTR?= MYjTRW5ITVJ?
ES6 M3XnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\J[YNKSzVyPUCuOVg3KG6P MoTsV2FPT0WU
EoL-1-cell NGry[HVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjjS|lPUUN3ME2wMlYyPiCwTR?= MkTLV2FPT0WU
NCI-H2009 M4\WUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL4bnpKSzVyPUCuOlE6KG6P NYW3S45xW0GQR1XS
A4-Fuk MojhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;hdGlEPTB;MD62NlYhdk1? M3e5SHNCVkeHUh?=
KYSE-270 NI\zVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXxXpVKUUN3ME2wMlY{PCCwTR?= MYPTRW5ITVJ?
SK-LU-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z3cmlEPTB;MD62OVUhdk1? M4DwTHNCVkeHUh?=
SW872 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLyTWM2OD1yLke2OUBvVQ>? NELMc|FUSU6JRWK=
ES8 NXfqU2JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwN{igcm0> NG\LWYxUSU6JRWK=
G-402 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwN{i0JI5O Mk\6V2FPT0WU
ATN-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj6TWM2OD1yLkiwO{BvVQ>? M1jRPHNCVkeHUh?=
DoTc2-4510 M{C5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjmNWx6UUN3ME2wMlkxOSCwTR?= Mn3ZV2FPT0WU
MES-SA MlruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;MTWM2OD1yLkmwOUBvVQ>? MWTTRW5ITVJ?
SF268 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTBwOUK3JI5O NUD5eY5yW0GQR1XS
SF539 NVnkU5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLxTWM2OD1zLkCyJI5O MVrTRW5ITVJ?
NB69 NXPzOVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HH[mlEPTB;MT6wOUBvVQ>? NYDibXV[W0GQR1XS
8505C MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13leWlEPTB;MT6wOkBvVQ>? NYflb|BLW0GQR1XS
CAL-12T MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfVV2dKSzVyPUGuNFghdk1? MnrDV2FPT0WU
BHY MnHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\4[4w1UUN3ME2xMlE1KG6P MkfPV2FPT0WU
LB647-SCLC NYnyWmdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMUigcm0> MXvTRW5ITVJ?
CAL-62 M4DEemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\PR|JKSzVyPUGuNlIhdk1? MnX4V2FPT0WU
MEG-01 M3zacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fvTGlEPTB;MT6yO{BvVQ>? MW\TRW5ITVJ?
MG-63 NVLhTY5pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLNSHhKSzVyPUGuN|Mhdk1? NX\ueI9jW0GQR1XS
SW620 NFjZbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHX2fZhKSzVyPUGuN|Uhdk1? MlX6V2FPT0WU
A388 Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\tTWlEPTB;MT6zOkBvVQ>? MlTCV2FPT0WU
BCPAP MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwNEWgcm0> M3nGOHNCVkeHUh?=
P30-OHK M1nobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HySGlEPTB;MT60OkBvVQ>? NIDXOJdUSU6JRWK=
Ca9-22 MkPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDxO4xKSzVyPUGuOVQhdk1? NEjONXZUSU6JRWK=
VMRC-RCZ M1fVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFwNUSgcm0> Mk\zV2FPT0WU
LOXIMVI MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojlTWM2OD1zLk[gcm0> MnHXV2FPT0WU
L-540 NHHF[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rneWlEPTB;MT62JI5O MULTRW5ITVJ?
NTERA-S-cl-D1 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzVTVV6UUN3ME2xMlY1KG6P MoPqV2FPT0WU
MFH-ino NX7IPXB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvBTWM2OD1zLk[2JI5O NUfGbopoW0GQR1XS
Calu-6 MkW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXnTWM2OD1zLkezJI5O MoLqV2FPT0WU
HEL M1zGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fxRmlEPTB;MT63PUBvVQ>? NETlUohUSU6JRWK=
CAL-33 NXTkcVBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;2T2lEPTB;MT64PUBvVQ>? M2rqUHNCVkeHUh?=
HSC-3 NX\vUJFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTFwOUGgcm0> MnLIV2FPT0WU
KU812 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PlRWlEPTB;MT65NUBvVQ>? MW\TRW5ITVJ?
EB2 NGjKVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\ZTWM2OD1{LkCxJI5O NXzudnlXW0GQR1XS
SR NYfKe5pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGntXWRKSzVyPUKuNVIhdk1? MlvuV2FPT0WU
NCI-H2087 MoHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDQVmZjUUN3ME2yMlE1KG6P MnTuV2FPT0WU
H4 NH\SfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFmweWtKSzVyPUKuNVghdk1? MXzTRW5ITVJ?
EW-1 M1H2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7O[2FKSzVyPUKuNlIhdk1? MlTIV2FPT0WU
MC-IXC M3jIWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjD[GlKSzVyPUKuNlYhdk1? M{Dr[XNCVkeHUh?=
NCI-H727 NU\x[mFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwNUGgcm0> Mn7MV2FPT0WU
MRK-nu-1 M4LXSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTrTWM2OD1{LkW3JI5O NHfLXGhUSU6JRWK=
COLO-668 NWL4UlBLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\PdpdKSzVyPUKuOlYhdk1? NHnrR2lUSU6JRWK=
CGTH-W-1 NHrHb|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PlOGlEPTB;Mj63NkBvVQ>? NXG0[HRvW0GQR1XS
CHP-212 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTjT4x1UUN3ME2yMlc2KG6P M3izOnNCVkeHUh?=
GI-1 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwN{[gcm0> NXPndVROW0GQR1XS
HCC1806 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvjTWM2OD1{LkmxJI5O MXTTRW5ITVJ?
HLE MoDGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DmbmlEPTB;MzDuUS=> M2PXRXNCVkeHUh?=
HSC-2 NH;kPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1r6fmlEPTB;Mz6wN{BvVQ>? NUT0bmVLW0GQR1XS
DMS-273 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTNwMEegcm0> MUPTRW5ITVJ?
DU-4475 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK4TWM2OD1|LkG0JI5O NGjU[ZlUSU6JRWK=
LXF-289 NXnq[ngxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3e2TWlEPTB;Mz6zNUBvVQ>? MmHmV2FPT0WU
PANC-03-27 MkmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\5TWM2OD1|LkWxJI5O NFz2Z4FUSU6JRWK=
GAMG M4PvTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDnUFVGUUN3ME2zMlc1KG6P NULNZYRrW0GQR1XS
NCI-H522 NIPLTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXVTWM2OD12LkO0JI5O M1m2eHNCVkeHUh?=
SW626 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRwNE[gcm0> MknZV2FPT0WU
HT-144 M2\FNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\ncWlEPTB;ND65NkBvVQ>? MX\TRW5ITVJ?
MEL-HO MmDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTVwMU[gcm0> MWLTRW5ITVJ?
BE-13 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PYb2lEPTB;NT6yNUBvVQ>? Mn:zV2FPT0WU
VA-ES-BJ MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PhXWlEPTB;NT6yOkBvVQ>? NWSwbI1nW0GQR1XS
NCI-H441 M4HPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTYUnVQUUN3ME21MlYhdk1? Ml3YV2FPT0WU
KP-4 M1Lrb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\PSXZKSzVyPUWuOlEhdk1? M{C1WnNCVkeHUh?=
LoVo M125Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3f1c2lEPTB;NT63NUBvVQ>? NF\NUFFUSU6JRWK=
HT-1080 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzVTWM2OD13LkizJI5O NGiwe|ZUSU6JRWK=
GB-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzaTWM2OD13Lki0JI5O MofTV2FPT0WU
IA-LM M3;UcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDiTWM2OD13LkmxJI5O MWLTRW5ITVJ?
8-MG-BA M1HiVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CxOmlEPTB;NT65N{BvVQ>? NH7XfnVUSU6JRWK=
SK-HEP-1 MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTZwMUSgcm0> NEXsZVNUSU6JRWK=
697 M4rjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nwUmlEPTB;Nj6yOUBvVQ>? MmPCV2FPT0WU
KYSE-450 Mo\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjOeoNZUUN3ME22MlMzKG6P M2WzcHNCVkeHUh?=
HCC2998 MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrTW|B2UUN3ME22MlM1KG6P M2\qXXNCVkeHUh?=
HD-MY-Z NIjX[odIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[wTWM2OD14Lk[4JI5O NEK3NplUSU6JRWK=
OS-RC-2 MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nZNWlEPTB;Nj62PEBvVQ>? MknJV2FPT0WU
SF126 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXUWoJKSzVyPUeuNFUhdk1? NV;6Z4x7W0GQR1XS
Ca-Ski NI\UO5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XpW2lEPTB;Nz6wPUBvVQ>? NH70T25USU6JRWK=
NCI-H358 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTdwMU[gcm0> NX\oXZpqW0GQR1XS
J82 NWq2cI84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MortTWM2OD15LkSxJI5O NW\4dXhVW0GQR1XS
NCI-H2342 NIH6ZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvmTWM2OD15Lk[zJI5O MVPTRW5ITVJ?
OVCAR-8 Mmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:0UYVQUUN3ME23Mlkhdk1? NH72eYtUSU6JRWK=
TE-8 M3qyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRThibl2= MkPMV2FPT0WU
ETK-1 MorUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHiT25QUUN3ME24MlA5KG6P MU\TRW5ITVJ?
HAL-01 NHjiNWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PxUWlEPTB;OD6yJI5O MoHpV2FPT0WU
KYSE-150 NWTMSGc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPNUJdKSzVyPUiuOFchdk1? NUXkXnJZW0GQR1XS
NCI-H810 NUTYWZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPOc|B[UUN3ME24MlU3KG6P NFXCdHFUSU6JRWK=
ONS-76 NF7wNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HtOGlEPTB;OD62PEBvVQ>? MlGxV2FPT0WU
NMC-G1 M4HQRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTDZ|hKSzVyPUiuO|Yhdk1? NUfVbXZqW0GQR1XS
C3A NWLRXppWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrSTWM2OD16Lki0JI5O M3GyZXNCVkeHUh?=
PA-1 NYPYcJl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRThwOUmgcm0> NUjyXJYzW0GQR1XS
SH-4 NEPHcW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjtPHVKSzVyPUmuNFIhdk1? MX7TRW5ITVJ?
EFO-27 NEPMZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULTUHlyUUN3ME25MlA2KG6P NYS5ZlFUW0GQR1XS
CAPAN-1 NUDWR5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\md2g4UUN3ME25MlI{KG6P NEHncolUSU6JRWK=
DU-145 M3XCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7kTWM2OD17LkK5JI5O M1m1VXNCVkeHUh?=
A101D NVLVNoxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTlwM{egcm0> M2HWU3NCVkeHUh?=
ST486 NELkVWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUmzVpdZUUN3ME25MlQyKG6P MX\TRW5ITVJ?
NCI-H1437 MoDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmyTWM2OD17LkSyJI5O NWfRPFRiW0GQR1XS
HGC-27 NHXFXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfBTWM2OD17Lk[gcm0> NInZelZUSU6JRWK=
8305C M2LsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTlwNkSgcm0> M1q3Z3NCVkeHUh?=
OCUB-M M4HFR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFyLkCzJI5O Ml\pV2FPT0WU
COLO-679 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFyLkC3JI5O NYfWd4ZtW0GQR1XS
Detroit562 NH3uSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVL2SYU3UUN3ME2xNE41OiCwTR?= NHy3fIlUSU6JRWK=
A204 M2TNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\NVXJvUUN3ME2xNU4yPiCwTR?= M{nWXHNCVkeHUh?=
NCI-H1734 NEfLXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXSZ2JHUUN3ME2xNU4zQSCwTR?= MV\TRW5ITVJ?
MC-CAR NWnGRolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zJNWlEPTB;MUGuOVghdk1? NFnaUWdUSU6JRWK=
NCI-H2170 M2DFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3DTWM2OD1zMT65O{BvVQ>? MYDTRW5ITVJ?
NCI-SNU-5 NHfnWItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTF{LkGzJI5O NH\hPZZUSU6JRWK=
HCE-T NWHjbGd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHP[pBKSzVyPUGyMlQzKG6P M4TzS3NCVkeHUh?=
KYSE-180 NXH5UXBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH74S5dKSzVyPUGyMlgyKG6P MoHiV2FPT0WU
C8166 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTOWJY2UUN3ME2xN{4xQCCwTR?= NF;lV5dUSU6JRWK=
NCI-H460 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDuTWM2OD1zMz61OEBvVQ>? MmLRV2FPT0WU
SNU-449 NFi3bmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF|Lke3JI5O NWDpO3BXW0GQR1XS
MDA-MB-468 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6xTWM2OD1zND6xNkBvVQ>? NXvEbFZDW0GQR1XS
COR-L23 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF2LkGzJI5O NXvSNYJQW0GQR1XS
CTV-1 M1jNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFracHpKSzVyPUG0MlE1KG6P M1PRcHNCVkeHUh?=
BL-41 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\QU2lEPTB;MUSuN|chdk1? NUizZZYyW0GQR1XS
IGR-1 NGf2N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSzTWM2OD1zND60NkBvVQ>? M3G1N3NCVkeHUh?=
TK10 NFLUTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;oVmlEPTB;MUSuOFkhdk1? NWfT[oJTW0GQR1XS
REH MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{n0SGlEPTB;MUSuOVEhdk1? M{P3cXNCVkeHUh?=
LU-139 NWHITFAxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFK0cG5KSzVyPUG0MlU6KG6P NE[2WVJUSU6JRWK=
KP-N-YS MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfLOXpuUUN3ME2xOE46PyCwTR?= NVTHW3J6W0GQR1XS
PANC-10-05 M{fPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzoeVBKSzVyPUG1MlM5KG6P NEXK[2tUSU6JRWK=
HL-60 NXTYT4diT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTSR5JKSzVyPUG1MlY6KG6P M{DUZXNCVkeHUh?=
T84 NIX5XJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETMbGtKSzVyPUG1Mlk3KG6P MnvJV2FPT0WU
RPMI-8226 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjtTWM2OD1zNj6wNkBvVQ>? MYnTRW5ITVJ?
UM-UC-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;5TWM2OD1zNj6xOkBvVQ>? MYfTRW5ITVJ?
TE-10 NITxU4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHXRYRKSzVyPUG2MlIyKG6P NHmwcoVUSU6JRWK=
CAL-148 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTF5LkKzJI5O NWX5bnJzW0GQR1XS
BV-173 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXnRoJKSzVyPUG3MlI4KG6P MVPTRW5ITVJ?
Calu-3 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjwSlJKSzVyPUG3MlI6KG6P MYPTRW5ITVJ?
RPMI-2650 M3LyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPnTWM2OD1zNz61PUBvVQ>? NH7MPJhUSU6JRWK=
MKN45 NULIbFdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\sZlBiUUN3ME2xO{44OyCwTR?= NEi3ZnFUSU6JRWK=
NUGC-3 NHvLU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvGTWM2OD1zOD6zOEBvVQ>? MYTTRW5ITVJ?
NCI-H520 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Hl[2lEPTB;MUiuO|chdk1? MXXTRW5ITVJ?
CCRF-CEM MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvZO3hKSzVyPUG4Mlg2KG6P NYXSXGVjW0GQR1XS
NCI-H2405 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LzOWlEPTB;MUmuNUBvVQ>? NFfPe49USU6JRWK=
ES7 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PUWmlEPTB;MUmuO|Yhdk1? NI\PPINUSU6JRWK=
BPH-1 NW\5XIxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTJyLkK4JI5O NF7oc5RUSU6JRWK=
SAS NX:3fZp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrqT3hCUUN3ME2yNE42KG6P M4nQPXNCVkeHUh?=
HuCCT1 MnPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJyLkW4JI5O M1LpUnNCVkeHUh?=
LOUCY MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjRTWM2OD1{MD62OkBvVQ>? NVHBVGkxW0GQR1XS
NCI-H292 NVLpO3hWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYi5Z2RxUUN3ME2yNE44QSCwTR?= MUXTRW5ITVJ?
G-361 M4X5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJzLkC3JI5O MmiyV2FPT0WU
M059J NVXGPWVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTJzLkC4JI5O Ml;jV2FPT0WU
NCI-H1651 NH3mWHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTJzLkGxJI5O M1u1T3NCVkeHUh?=
KALS-1 M{PQPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJzLkO5JI5O NHXxZYtUSU6JRWK=
DJM-1 NUHC[41zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFWzd2dKSzVyPUKxMlU6KG6P MmjpV2FPT0WU
AU565 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3kRWhKSzVyPUKxMlg{KG6P MWDTRW5ITVJ?
HCC38 MnHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDublZYUUN3ME2yNU46PSCwTR?= NYfWZnM2W0GQR1XS
U251 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvYU4dbUUN3ME2yNk4zPyCwTR?= M4\5PXNCVkeHUh?=
ABC-1 NVe1elYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\mNJdKSzVyPUKyMlY2KG6P MmLCV2FPT0WU
SK-NEP-1 NHTzfIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GyRmlEPTB;MkKuPVMhdk1? NHWyUmtUSU6JRWK=
CESS NX;sOVRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHTTWM2OD1{Mz6xPUBvVQ>? Mn23V2FPT0WU
MIA-PaCa-2 MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJ|LkO2JI5O M3TMRXNCVkeHUh?=
SUP-T1 NHjrSo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTJ|LkS3JI5O NGO5RlFUSU6JRWK=
L-428 NW\k[4R3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjVTWM2OD1{Mz62NkBvVQ>? MmfwV2FPT0WU
SW954 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3WTWM2OD1{Mz62PEBvVQ>? MWXTRW5ITVJ?
HO-1-N-1 NInPXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M370OWlEPTB;MkOuO|chdk1? NHXZe3NUSU6JRWK=
CHP-126 Mo\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXMZVFKSzVyPUK0MlE1KG6P NVnZVI4zW0GQR1XS
HMV-II NEPhSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ2LkO0JI5O M4j2VHNCVkeHUh?=
NB10 NE\xTZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYH2PYVlUUN3ME2yOE4{PyCwTR?= NYHsXGY1W0GQR1XS
A172 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XMfGlEPTB;MkSuO|Ehdk1? M2LMSHNCVkeHUh?=
MONO-MAC-6 MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3DS5ZKSzVyPUK0Mlg1KG6P M{ToSnNCVkeHUh?=
NCI-H1650 NG\6O4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHmdWJvUUN3ME2yOU41KG6P NIXWbllUSU6JRWK=
NH-12 NXXhTZJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjGcIhKSzVyPUK1MlUhdk1? M{i4W3NCVkeHUh?=
ML-2 NFK5[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHNTWM2OD1{NT63OEBvVQ>? MXrTRW5ITVJ?
MZ2-MEL M3:0Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH1TWM2OD1{Nj6yNkBvVQ>? MWfTRW5ITVJ?
COLO-684 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLlTWM2OD1{Nj60NUBvVQ>? NG[2dHdUSU6JRWK=
HuP-T4 MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF75O4FKSzVyPUK3MlMhdk1? NULGOJZYW0GQR1XS
SW837 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\oNWlEPTB;MkeuOlIhdk1? M1r1UnNCVkeHUh?=
MDA-MB-231 NHfYdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{m3NmlEPTB;MkeuO|ghdk1? M1zlTnNCVkeHUh?=
KYSE-140 M2HxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnMSW5mUUN3ME2yO{46OSCwTR?= NITWZ|dUSU6JRWK=
NOMO-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LDSGlEPTB;MkiuOlghdk1? MlvCV2FPT0WU
GP5d NXHtfplRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXmTWM2OD1{OD63NkBvVQ>? MVLTRW5ITVJ?
COR-L105 M{XqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XpRWlEPTB;MkmuOFIhdk1? NVGyW3c3W0GQR1XS
LS-411N NF7kdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ7Lki4JI5O MoqwV2FPT0WU
NY MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HmSmlEPTB;M{CuNVghdk1? M{\TbnNCVkeHUh?=
NCI-H2030 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXFNVJKSzVyPUOwMlQ2KG6P NFjPO|VUSU6JRWK=
CCF-STTG1 NIq3SXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLGdFhpUUN3ME2zNU41OiCwTR?= NWGze497W0GQR1XS
NCI-H1703 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPlTZJKSzVyPUOxMlc5KG6P MmLsV2FPT0WU
TUR NXvZcIRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XTVGlEPTB;M{KuNFMhdk1? MWjTRW5ITVJ?
NOS-1 M3jTT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTN{LkS0JI5O NHTqfJVUSU6JRWK=
A2058 MkLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN{LkizJI5O M2P4PXNCVkeHUh?=
LCLC-103H NFjYeoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPye4NvUUN3ME2zN{4zPSCwTR?= M37rU3NCVkeHUh?=
NCI-H510A NEn4bGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfzTWM2OD1|Mz6yO{BvVQ>? MW\TRW5ITVJ?
BC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTN|Lke3JI5O Mk\rV2FPT0WU
SK-CO-1 NH\SWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTxTWM2OD1|ND6wNUBvVQ>? NUDIXoE1W0GQR1XS
A673 NX;Q[2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTN2LkG3JI5O NYHK[WQ4W0GQR1XS
VM-CUB-1 NIjUOFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfQTWM2OD1|ND62PUBvVQ>? NWPnVYhoW0GQR1XS
HH NFr5R5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfqTWM2OD1|NT6wOkBvVQ>? MlLuV2FPT0WU
CAL-27 M2j4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXkRXhKSzVyPUO1MlE3KG6P NXG5WJFtW0GQR1XS
NEC8 NIrJbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HUOGlEPTB;M{WuN|chdk1? NF\lT5pUSU6JRWK=
BxPC-3 NXfwSnV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLSTWM2OD1|Nj65NUBvVQ>? NX;ERpNbW0GQR1XS
SNB75 M2O2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXBTWM2OD1|Nz6yOEBvVQ>? MkW5V2FPT0WU
NB13 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1PWhKSzVyPUO4MlI{KG6P NGOwcoxUSU6JRWK=
SK-OV-3 NYXncZNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjGTWM2OD1|OD63OEBvVQ>? M3HTSHNCVkeHUh?=
ME-180 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTN6Lkigcm0> NGjHdZZUSU6JRWK=
JiyoyeP-2003 M{H6fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3WOYZKSzVyPUO5MlM5KG6P MkS3V2FPT0WU
LU-134-A NEfNOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTRyLkCyJI5O NV3lUJpWW0GQR1XS
LS-123 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\yTWM2OD12MD6yPEBvVQ>? MULTRW5ITVJ?
COLO-800 M2C2NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;QTWM2OD12MD61OkBvVQ>? NXnOXnZqW0GQR1XS
LB831-BLC MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XuRmlEPTB;NEGuPFUhdk1? MVzTRW5ITVJ?
NCI-H747 M4Tj[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOVY52UUN3ME20Nk4zQCCwTR?= NGP6d2xUSU6JRWK=
MZ7-mel NGDFT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\mUIFKSzVyPUSyMlY3KG6P NGfSVWlUSU6JRWK=
GT3TKB MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLXRnNKSzVyPUSyMlczKG6P NGfkUZNUSU6JRWK=
MOLT-16 MnvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTR|LkC1JI5O MWPTRW5ITVJ?
23132-87 Mn3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrTdHFlUUN3ME20N{4xPSCwTR?= MXLTRW5ITVJ?
PF-382 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrx[FNKSzVyPUS0MlIzKG6P MVvTRW5ITVJ?
ES3 NEXtS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PsSWlEPTB;NESuOkBvVQ>? MYrTRW5ITVJ?
SW756 NUficXliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTuTWM2OD12NT6xOEBvVQ>? NWLmfYtRW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p70S6K1 / p-S6 / HIF-1α ; 

PubMed: 27765914     


Cells were treated with different doses of gemcitabine (0, 1.5 and 2.5 μM), the expression levels of p70S6K1, p-S6 and HIF-1α were determined by Western blotting. GAPDH is used as an internal control.

PARP / Cleaved PARP / Cleaved caspase-3 / phopho-p38 / p38 / p-JNK / JNK / p-c-Jun; 

PubMed: 24409315     


AsPC-1, BxPC-3, and COLO-357 cells were incubated for the indicated times with 100 ng/ml, 10 ng/ml, and 5 ng/ml gemcitabine, respectively, and analyzed by immunoblotting. 

27765914 24409315
Immunofluorescence
Bim1; 

PubMed: 27177084     


Gemcitabine enhanced nuclear accumulation of Bmi1 by immunofluorescence staining. The graphs shown are representative results of three independently repeated experiments. Scale bar, 50 μm.

27177084
Growth inhibition assay
Cell viability; 

PubMed: 27765914     


A and B. Pancreatic adenocarcinoma cells Bxpc-3 (A) and Panc-1 (B) were treated with gemcitabine (GEM) for 48 h at different doses. The cell viability was analyzed by CCK-8 assay, and normalized to cells without gemcitabine treatment. 

27765914
In vivo Gemcitabine combined with C225 results in growth inhibition, tumor regression, and abrogation of metastasis in L3.6pl tumors established in the pancreas of nude mice. Gemcitabine treatment alone reduces median tumor volume from 538 to 152 mm3. Gemcitabine reduces the production of vascular endothelial growth factor and interleukin 8 in gemcitabine-treated tumors. [2] Gemcitabine is able to dramatically and specifically reduces the number of myeloid suppressor cells found in the spleens of animals bearing large tumors with no significant reductions in CD4(+) T cells, CD8(+) T cells, NK cells, macrophages, or B cells. [4] Gemcitabine combined with curcumin shows significant reductions in volume (P = 0.008 versus control; P = 0.036 versus gemcitabine alone), Ki-67 proliferation index (P = 0.030 versus control), NF-kappaB activation, and expression of NF-kappaB-regulated gene products (cyclin D1, c-myc, Bcl-2, Bcl-xL, cellular inhibitor of apoptosis protein-1, cyclooxygenase-2, matrix metalloproteinase, and vascular endothelial growth factor) compared with tumors from control mice treated with olive oil only. Gemcitabine combined with Curcumin is also highly effective in suppressing angiogenesis as indicated by a decrease in CD31(+) microvessel density. [5]

Protocol

Solubility (25°C)

In vitro DMSO 52 mg/mL (197.56 mM)
Water 52 mg/mL warmed (197.56 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water (warmed)
For best results, use promptly after mixing.
52mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 263.2
Formula

C9H11F2N3O4

CAS No. 95058-81-4
Storage powder
in solvent
Synonyms LY-188011, NSC 613327
Smiles NC1=NC(=O)N(C=C1)C2OC(CO)C(O)C2(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04383119 Not yet recruiting Drug: Trabectedin|Drug: Gemcitabine Leiomyosarcoma of Ovary|Soft Tissue Sarcoma Italian Sarcoma Group|PharmaMar September 1 2020 Phase 2
NCT04338763 Not yet recruiting Drug: RP72|Drug: Gemcitabine Pancreatic Cancer|Pancreatic Cancer Non-resectable|Pancreatic Cancer Metastatic Rise Biopharmaceuticals Inc.|Amarex Clinical Research April 30 2020 Phase 1
NCT04241276 Not yet recruiting Drug: ATRA|Drug: Gemcitabine|Drug: nab-paclitaxel Pancreatic Cancer Queen Mary University of London|Medical Research Council|Celgene April 30 2020 Phase 2
NCT03773302 Recruiting Drug: BGJ398|Drug: Gemcitabine|Drug: Cisplatin Advanced Cholangiocarcinoma|FGFR2 Gene Mutation QED Therapeutics Inc. December 27 2019 Phase 3
NCT04051047 Withdrawn Drug: Gemcitabine|Procedure: Tumor biopsy and blood draw Glial Tumor of Brain|Diffuse Intrinsic Pontine Glioma|Glioma University of Michigan Rogel Cancer Center|University of Colorado Denver November 30 2019 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What is the difference between gemcitabine(S1714 ) and Gemcitabine HCl (S1149)?

  • Answer:

    Gemcitabine HCl is the HCl salt form of Gemcitabine. They have the same biological activities. The free base(S1714) dissolves better in DMSO, and the hydrochloride (S1149) dissolves better in water.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Gemcitabine | Gemcitabine ic50 | Gemcitabine price | Gemcitabine cost | Gemcitabine solubility dmso | Gemcitabine purchase | Gemcitabine manufacturer | Gemcitabine research buy | Gemcitabine order | Gemcitabine mouse | Gemcitabine chemical structure | Gemcitabine mw | Gemcitabine molecular weight | Gemcitabine datasheet | Gemcitabine supplier | Gemcitabine in vitro | Gemcitabine cell line | Gemcitabine concentration | Gemcitabine nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID